Skip to main content
Top

Open Access 06-03-2024 | Pneumonia | Original Research

Staphylococcus aureus Pneumonia in Can Tho, Vietnam: Clinical Characteristics, Antimicrobial Resistance Profile and Risk Factors of Mortality

Authors: Thu Vo-Pham-Minh, Dang Tran-Cong, Hung Phan-Viet, Thien Dinh-Chi, Tran Nguyen-Thi-Hong, Thuy Cao-Thi-My, Hien Nguyen-Thi-Dieu, Duong Vo-Thai, Vu Nguyen-Thien, Sy Duong-Quy

Published in: Pulmonary Therapy

Login to get access

Abstract

Introduction

Staphylococcus aureus (S. aureus) is an important pathogen in both community-acquired and hospital-acquired pneumonia. S. aureus pneumonia has a high mortality rate and serious complications. Resistance to multiple antibiotics is a major challenge in the treatment of S. aureus pneumonia. Understanding the antibiotic resistance profile of S. aureus and the risk factors for mortality can help optimize antibiotic regimens and improve patient outcomes in S. aureus pneumonia.

Methods

A prospective cohort study of 118 patients diagnosed with S. aureus pneumonia between May 2021 and June 2023 was conducted, with a 30-day follow-up period. Demographic information, comorbidities, Charlson Comorbidity Index, clinical characteristics, outcomes, and complications were collected for each enrolled case. The data were processed and analyzed using R version 3.6.2.

Results

S. aureus pneumonia has a 30-day mortality rate of approximately 50%, with complication rates of 22% for acute respiratory distress syndrome (ARDS), 26.3% for septic shock, and 14.4% for acute kidney injury (AKI). Among patients with methicillin-resistant S. aureus (MRSA) pneumonia treated with vancomycin (n = 40), those with a vancomycin minimum inhibitory concentration (MIC) ≤ 1 had significantly higher cumulative survival at day 30 compared to those with MIC ≥ 2 (log-rank test p = 0.04). The prevalence of MRSA among S. aureus isolates was 84.7%. Hemoptysis, methicillin resistance, acidosis (pH < 7.35), and meeting the Infectious Diseases Society of America/American Thoracic Society (IDSA/ATS) criteria for severe pneumonia were significantly associated with mortality in a multivariate Cox regression model based on the adaptive least absolute shrinkage and selection operator (LASSO).

Conclusions

S. aureus pneumonia is a severe clinical condition with high mortality and complication rates. MRSA has a high prevalence in Can Tho City, Vietnam. Hemoptysis, methicillin resistance, acidosis (pH < 7.35), and meeting the IDSA/ATS criteria for severe pneumonia are risk factors for mortality in S. aureus pneumonia.
Literature
1.
go back to reference Ahmad-Mansour N, Loubet P, Pouget C, et al. Staphylococcus aureus toxins: an update on their pathogenic properties and potential treatments. Toxins (Basel). 2021;13(10):677.PubMedCrossRef Ahmad-Mansour N, Loubet P, Pouget C, et al. Staphylococcus aureus toxins: an update on their pathogenic properties and potential treatments. Toxins (Basel). 2021;13(10):677.PubMedCrossRef
2.
go back to reference Althaqafi AO, Matar MJ, Moghnieh R, et al. Burden of methicillin-resistant Staphylococcus aureus pneumonia among hospitalized patients in Lebanon and Saudi Arabia. Infect Drug Resist. 2017;10:49–55.PubMedPubMedCentralCrossRef Althaqafi AO, Matar MJ, Moghnieh R, et al. Burden of methicillin-resistant Staphylococcus aureus pneumonia among hospitalized patients in Lebanon and Saudi Arabia. Infect Drug Resist. 2017;10:49–55.PubMedPubMedCentralCrossRef
3.
go back to reference Benhamou D, Carrie AS, Lecomte F. Staphylococcus aureus: role and impact in the treatment of nosocomial pneumonia. Rev Mal Respir. 2005;22(4):595–603.PubMedCrossRef Benhamou D, Carrie AS, Lecomte F. Staphylococcus aureus: role and impact in the treatment of nosocomial pneumonia. Rev Mal Respir. 2005;22(4):595–603.PubMedCrossRef
4.
go back to reference Boussaud V, Parrot A, Mayaud C, et al. Life-threatening hemoptysis in adults with community-acquired pneumonia due to Panton-Valentine leukocidin-secreting Staphylococcus aureus. Intensive Care Med. 2003;29(10):1840–3.PubMedPubMedCentralCrossRef Boussaud V, Parrot A, Mayaud C, et al. Life-threatening hemoptysis in adults with community-acquired pneumonia due to Panton-Valentine leukocidin-secreting Staphylococcus aureus. Intensive Care Med. 2003;29(10):1840–3.PubMedPubMedCentralCrossRef
7.
go back to reference Charles PG, Wolfe R, Whitby M, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008;47(3):375–84.PubMedCrossRef Charles PG, Wolfe R, Whitby M, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008;47(3):375–84.PubMedCrossRef
8.
go back to reference Charlson ME, Charlson RE, Peterson JC, et al. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol. 2008;61(12):1234–40.PubMedCrossRef Charlson ME, Charlson RE, Peterson JC, et al. The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients. J Clin Epidemiol. 2008;61(12):1234–40.PubMedCrossRef
9.
go back to reference Choi EY, Huh JW, Lim CM, et al. Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial pneumonia. Intensive Care Med. 2011;37(4):639–47.PubMedCrossRef Choi EY, Huh JW, Lim CM, et al. Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial pneumonia. Intensive Care Med. 2011;37(4):639–47.PubMedCrossRef
10.
go back to reference Cilloniz C, Dominedo C, Gabarrus A, et al. Methicillin-susceptible Staphylococcus aureus in community-acquired pneumonia: risk factors and outcomes. J Infect. 2021;82(1):76–83.PubMedCrossRef Cilloniz C, Dominedo C, Gabarrus A, et al. Methicillin-susceptible Staphylococcus aureus in community-acquired pneumonia: risk factors and outcomes. J Infect. 2021;82(1):76–83.PubMedCrossRef
11.
go back to reference Cilloniz C, Ewig S, Gabarrus A, et al. Seasonality of pathogens causing community-acquired pneumonia. Respirology. 2017;22(4):778–85.PubMedCrossRef Cilloniz C, Ewig S, Gabarrus A, et al. Seasonality of pathogens causing community-acquired pneumonia. Respirology. 2017;22(4):778–85.PubMedCrossRef
12.
go back to reference Collaborators GL. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis. 2017;17(11):1133–61.CrossRef Collaborators GL. Estimates of the global, regional, and national morbidity, mortality, and aetiologies of lower respiratory tract infections in 195 countries: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Infect Dis. 2017;17(11):1133–61.CrossRef
13.
go back to reference De la Calle C, Morata L, Cobos-Trigueros N, et al. Staphylococcus aureus bacteremic pneumonia. Eur J Clin Microbiol Infect Dis. 2016;35(3):497–502.PubMedCrossRef De la Calle C, Morata L, Cobos-Trigueros N, et al. Staphylococcus aureus bacteremic pneumonia. Eur J Clin Microbiol Infect Dis. 2016;35(3):497–502.PubMedCrossRef
14.
go back to reference Espana PP, Capelastegui A, Gorordo I, et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med. 2006;174(11):1249–56.PubMedCrossRef Espana PP, Capelastegui A, Gorordo I, et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med. 2006;174(11):1249–56.PubMedCrossRef
15.
go back to reference File TM Jr, Low DE, Eckburg PB, et al. FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66(Suppl 3):iii19-32.PubMed File TM Jr, Low DE, Eckburg PB, et al. FOCUS 1: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66(Suppl 3):iii19-32.PubMed
16.
go back to reference Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243–50.PubMedCrossRef Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997;336(4):243–50.PubMedCrossRef
17.
go back to reference Force ADT, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012;307(23):2526–33. Force ADT, Ranieri VM, Rubenfeld GD, et al. Acute respiratory distress syndrome: the Berlin definition. JAMA. 2012;307(23):2526–33.
18.
go back to reference Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet. 2002;359(9308):753–9.PubMedCrossRef Gillet Y, Issartel B, Vanhems P, et al. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients. Lancet. 2002;359(9308):753–9.PubMedCrossRef
19.
go back to reference Gillet Y, Tristan A, Rasigade JP, et al. Prognostic factors of severe community-acquired staphylococcal pneumonia in France. Eur Respir J. 2021;58(5):2004445.PubMedPubMedCentralCrossRef Gillet Y, Tristan A, Rasigade JP, et al. Prognostic factors of severe community-acquired staphylococcal pneumonia in France. Eur Respir J. 2021;58(5):2004445.PubMedPubMedCentralCrossRef
20.
go back to reference Gillet Y, Vanhems P, Lina G, et al. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis. 2007;45(3):315–21.PubMedCrossRef Gillet Y, Vanhems P, Lina G, et al. Factors predicting mortality in necrotizing community-acquired pneumonia caused by Staphylococcus aureus containing Panton-Valentine leukocidin. Clin Infect Dis. 2007;45(3):315–21.PubMedCrossRef
21.
go back to reference Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003–04 influenza season. Emerg Infect Dis. 2006;12(6):894–9.PubMedPubMedCentralCrossRef Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003–04 influenza season. Emerg Infect Dis. 2006;12(6):894–9.PubMedPubMedCentralCrossRef
22.
go back to reference Haque NZ, Zuniga LC, Peyrani P, et al. Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia. Chest. 2010;138(6):1356–62.PubMedCrossRef Haque NZ, Zuniga LC, Peyrani P, et al. Relationship of vancomycin minimum inhibitory concentration to mortality in patients with methicillin-resistant Staphylococcus aureus hospital-acquired, ventilator-associated, or health-care-associated pneumonia. Chest. 2010;138(6):1356–62.PubMedCrossRef
23.
go back to reference He H, Wunderink RG. Staphylococcus aureus pneumonia in the community. Semin Respir Crit Care Med. 2020;41(4):470–9.PubMedCrossRef He H, Wunderink RG. Staphylococcus aureus pneumonia in the community. Semin Respir Crit Care Med. 2020;41(4):470–9.PubMedCrossRef
24.
25.
go back to reference Jung WJ, Kang YA, Park MS, et al. Prediction of methicillin-resistant Staphylococcus aureus in patients with non-nosocomial pneumonia. BMC Infect Dis. 2013;13:370.PubMedPubMedCentralCrossRef Jung WJ, Kang YA, Park MS, et al. Prediction of methicillin-resistant Staphylococcus aureus in patients with non-nosocomial pneumonia. BMC Infect Dis. 2013;13:370.PubMedPubMedCentralCrossRef
26.
go back to reference Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61–111.PubMedPubMedCentralCrossRef Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016;63(5):e61–111.PubMedPubMedCentralCrossRef
27.
go back to reference Khanafer N, Sicot N, Vanhems P, et al. Severe leukopenia in Staphylococcus aureus-necrotizing, community-acquired pneumonia: risk factors and impact on survival. BMC Infect Dis. 2013;13:359.PubMedPubMedCentralCrossRef Khanafer N, Sicot N, Vanhems P, et al. Severe leukopenia in Staphylococcus aureus-necrotizing, community-acquired pneumonia: risk factors and impact on survival. BMC Infect Dis. 2013;13:359.PubMedPubMedCentralCrossRef
28.
go back to reference Kontou P, Kuti JL, Nicolau DP. Validation of the Infectious Diseases Society of America/American Thoracic Society criteria to predict severe community-acquired pneumonia caused by Streptococcus pneumoniae. Am J Emerg Med. 2009;27(8):968–74.PubMedCrossRef Kontou P, Kuti JL, Nicolau DP. Validation of the Infectious Diseases Society of America/American Thoracic Society criteria to predict severe community-acquired pneumonia caused by Streptococcus pneumoniae. Am J Emerg Med. 2009;27(8):968–74.PubMedCrossRef
29.
go back to reference Labandeira-Rey M, Couzon F, Boisset S, et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science. 2007;315(5815):1130–3.ADSPubMedCrossRef Labandeira-Rey M, Couzon F, Boisset S, et al. Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia. Science. 2007;315(5815):1130–3.ADSPubMedCrossRef
30.
go back to reference Li HT, Zhang TT, Huang J, et al. Factors associated with the outcome of life-threatening necrotizing pneumonia due to community-acquired Staphylococcus aureus in adult and adolescent patients. Respiration. 2011;81(6):448–60.PubMedCrossRef Li HT, Zhang TT, Huang J, et al. Factors associated with the outcome of life-threatening necrotizing pneumonia due to community-acquired Staphylococcus aureus in adult and adolescent patients. Respiration. 2011;81(6):448–60.PubMedCrossRef
31.
go back to reference Loffler B, Niemann S, Ehrhardt C, et al. Pathogenesis of Staphylococcus aureus necrotizing pneumonia: the role of PVL and an influenza coinfection. Expert Rev Anti Infect Ther. 2013;11(10):1041–51.PubMedCrossRef Loffler B, Niemann S, Ehrhardt C, et al. Pathogenesis of Staphylococcus aureus necrotizing pneumonia: the role of PVL and an influenza coinfection. Expert Rev Anti Infect Ther. 2013;11(10):1041–51.PubMedCrossRef
32.
go back to reference Low DE, File TM Jr, Eckburg PB, et al. FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66(Suppl 3):iii33-44.PubMedCrossRef Low DE, File TM Jr, Eckburg PB, et al. FOCUS 2: a randomized, double-blinded, multicentre, phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66(Suppl 3):iii33-44.PubMedCrossRef
33.
go back to reference Machado DP, Goldani LZ, Paiva RM, et al. The impact of serum vancomycin levels and minimum inhibitory concentrations of methicillin-resistant Staphylococcus aureus on mortality in patients with nosocomial pneumonia. Can J Infect Dis Med Microbiol. 2013;24(3):e75–9.PubMedPubMedCentralCrossRef Machado DP, Goldani LZ, Paiva RM, et al. The impact of serum vancomycin levels and minimum inhibitory concentrations of methicillin-resistant Staphylococcus aureus on mortality in patients with nosocomial pneumonia. Can J Infect Dis Med Microbiol. 2013;24(3):e75–9.PubMedPubMedCentralCrossRef
34.
go back to reference Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45–67.PubMedPubMedCentralCrossRef Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45–67.PubMedPubMedCentralCrossRef
35.
go back to reference Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008;46(Suppl 5):S378–85.PubMedCrossRef Rubinstein E, Kollef MH, Nathwani D. Pneumonia caused by methicillin-resistant Staphylococcus aureus. Clin Infect Dis. 2008;46(Suppl 5):S378–85.PubMedCrossRef
36.
go back to reference Ruiz-Ramos J, Vidal-Cortes P, Diaz-Lamas A, et al. Ventilator-associated pneumonia by methicillin-susceptible Staphylococcus aureus: do minimum inhibitory concentrations to vancomycin and daptomycin matter? Eur J Clin Microbiol Infect Dis. 2017;36(9):1569–75.PubMedCrossRef Ruiz-Ramos J, Vidal-Cortes P, Diaz-Lamas A, et al. Ventilator-associated pneumonia by methicillin-susceptible Staphylococcus aureus: do minimum inhibitory concentrations to vancomycin and daptomycin matter? Eur J Clin Microbiol Infect Dis. 2017;36(9):1569–75.PubMedCrossRef
37.
go back to reference Self WH, Wunderink RG, Williams DJ, et al. Staphylococcus aureus community-acquired pneumonia: prevalence, clinical characteristics, and outcomes. Clin Infect Dis. 2016;63(3):300–9.PubMedCrossRef Self WH, Wunderink RG, Williams DJ, et al. Staphylococcus aureus community-acquired pneumonia: prevalence, clinical characteristics, and outcomes. Clin Infect Dis. 2016;63(3):300–9.PubMedCrossRef
38.
go back to reference Shorr AFCA, Kollef MH, Chastre J, et al. Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Crit Care. 2006;10(3):R97.PubMedPubMedCentralCrossRef Shorr AFCA, Kollef MH, Chastre J, et al. Morbidity and cost burden of methicillin-resistant Staphylococcus aureus in early onset ventilator-associated pneumonia. Crit Care. 2006;10(3):R97.PubMedPubMedCentralCrossRef
39.
go back to reference Shorr AF, Haque N, Taneja C, et al. Clinical and economic outcomes for patients with health care-associated Staphylococcus aureus pneumonia. J Clin Microbiol. 2010;48(9):3258–62.PubMedPubMedCentralCrossRef Shorr AF, Haque N, Taneja C, et al. Clinical and economic outcomes for patients with health care-associated Staphylococcus aureus pneumonia. J Clin Microbiol. 2010;48(9):3258–62.PubMedPubMedCentralCrossRef
40.
go back to reference Sicot N, Khanafer N, Meyssonnier V, et al. Methicillin resistance is not a predictor of severity in community-acquired Staphylococcus aureus necrotizing pneumonia–results of a prospective observational study. Clin Microbiol Infect. 2013;19(3):E142–8.PubMedCrossRef Sicot N, Khanafer N, Meyssonnier V, et al. Methicillin resistance is not a predictor of severity in community-acquired Staphylococcus aureus necrotizing pneumonia–results of a prospective observational study. Clin Microbiol Infect. 2013;19(3):E142–8.PubMedCrossRef
41.
go back to reference Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–10.PubMedPubMedCentralCrossRef Singer M, Deutschman CS, Seymour CW, et al. The third international consensus definitions for sepsis and septic shock (Sepsis-3). JAMA. 2016;315(8):801–10.PubMedPubMedCentralCrossRef
42.
go back to reference Stets R, Popescu M, Gonong JR, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019;380(6):517–27.PubMedCrossRef Stets R, Popescu M, Gonong JR, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019;380(6):517–27.PubMedCrossRef
43.
go back to reference Tacconelli E, De Angelis G. Pneumonia due to methicillin-resistant Staphylococcus aureus: clinical features, diagnosis and management. Curr Opin Pulm Med. 2009;15(3):218–22.PubMedCrossRef Tacconelli E, De Angelis G. Pneumonia due to methicillin-resistant Staphylococcus aureus: clinical features, diagnosis and management. Curr Opin Pulm Med. 2009;15(3):218–22.PubMedCrossRef
44.
go back to reference Tadros M, Williams V, Coleman BL, et al. Epidemiology and outcome of pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) in Canadian hospitals. PLoS ONE. 2013;8(9): e75171.ADSPubMedPubMedCentralCrossRef Tadros M, Williams V, Coleman BL, et al. Epidemiology and outcome of pneumonia caused by methicillin-resistant Staphylococcus aureus (MRSA) in Canadian hospitals. PLoS ONE. 2013;8(9): e75171.ADSPubMedPubMedCentralCrossRef
45.
go back to reference Thabet N, Shindo Y, Okumura J, et al. Clinical characteristics and risk factors for mortality in patients with community-acquired staphylococcal pneumonia. Nagoya J Med Sci. 2022;84(2):247–59.PubMedPubMedCentral Thabet N, Shindo Y, Okumura J, et al. Clinical characteristics and risk factors for mortality in patients with community-acquired staphylococcal pneumonia. Nagoya J Med Sci. 2022;84(2):247–59.PubMedPubMedCentral
46.
go back to reference Tilouche L, Ben DR, Boughattas S, et al. Staphylococcus aureus ventilator-associated pneumonia: a study of bacterio-epidemiological profile and virulence factors. Curr Microbiol. 2021;78(7):2556–62.PubMedPubMedCentralCrossRef Tilouche L, Ben DR, Boughattas S, et al. Staphylococcus aureus ventilator-associated pneumonia: a study of bacterio-epidemiological profile and virulence factors. Curr Microbiol. 2021;78(7):2556–62.PubMedPubMedCentralCrossRef
47.
go back to reference Tran KQ, Nguyen TTD, Pham VH, et al. Pathogenic role and antibiotic resistance of methicillin-resistant Staphylococcus aureus (MRSA) strains causing severe community-acquired pneumonia in Vietnamese children. Adv Respir Med. 2023;91(2):135–45.PubMedPubMedCentralCrossRef Tran KQ, Nguyen TTD, Pham VH, et al. Pathogenic role and antibiotic resistance of methicillin-resistant Staphylococcus aureus (MRSA) strains causing severe community-acquired pneumonia in Vietnamese children. Adv Respir Med. 2023;91(2):135–45.PubMedPubMedCentralCrossRef
48.
go back to reference van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012;54(6):755–71.PubMedCrossRef van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012;54(6):755–71.PubMedCrossRef
50.
go back to reference Vlaeminck J, Raafat D, Surmann K, et al. Exploring virulence factors and alternative therapies against Staphylococcus aureus pneumonia. Toxins (Basel). 2020;12(11):721.PubMedCrossRef Vlaeminck J, Raafat D, Surmann K, et al. Exploring virulence factors and alternative therapies against Staphylococcus aureus pneumonia. Toxins (Basel). 2020;12(11):721.PubMedCrossRef
51.
go back to reference Woods C, Colice G. Methicillin-resistant Staphylococcus aureus pneumonia in adults. Expert Rev Respir Med. 2014;8(5):641–51.PubMedCrossRef Woods C, Colice G. Methicillin-resistant Staphylococcus aureus pneumonia in adults. Expert Rev Respir Med. 2014;8(5):641–51.PubMedCrossRef
52.
go back to reference Zhang QR, Chen H, Liu B, et al. Methicillin-resistant Staphylococcus aureus pneumonia in diabetics: a single-center, retrospective analysis. Chin Med J (Engl). 2019;132(12):1429–34.PubMedCrossRef Zhang QR, Chen H, Liu B, et al. Methicillin-resistant Staphylococcus aureus pneumonia in diabetics: a single-center, retrospective analysis. Chin Med J (Engl). 2019;132(12):1429–34.PubMedCrossRef
53.
go back to reference Dumitrescu O, Badiou C, Bes M, et al. Effect of antibiotics, alone and in combination, on panton-valentine leukocidin production by a Staphylococcus aureus reference strain. Clin Microbiol Infect. 2008;14(4):384–8.PubMedCrossRef Dumitrescu O, Badiou C, Bes M, et al. Effect of antibiotics, alone and in combination, on panton-valentine leukocidin production by a Staphylococcus aureus reference strain. Clin Microbiol Infect. 2008;14(4):384–8.PubMedCrossRef
54.
go back to reference Dumitrescu O, Boisset S, Badiou C, et al. Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin. Antimicrob Agents Chemother. 2007;51(4):1515–9.PubMedPubMedCentralCrossRef Dumitrescu O, Boisset S, Badiou C, et al. Effect of antibiotics on Staphylococcus aureus producing Panton-Valentine leukocidin. Antimicrob Agents Chemother. 2007;51(4):1515–9.PubMedPubMedCentralCrossRef
55.
go back to reference Marti C, Garin N, Grosgurin O, et al. Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Crit Care. 2012;16(4):R141.PubMedPubMedCentralCrossRef Marti C, Garin N, Grosgurin O, et al. Prediction of severe community-acquired pneumonia: a systematic review and meta-analysis. Crit Care. 2012;16(4):R141.PubMedPubMedCentralCrossRef
Metadata
Title
Staphylococcus aureus Pneumonia in Can Tho, Vietnam: Clinical Characteristics, Antimicrobial Resistance Profile and Risk Factors of Mortality
Authors
Thu Vo-Pham-Minh
Dang Tran-Cong
Hung Phan-Viet
Thien Dinh-Chi
Tran Nguyen-Thi-Hong
Thuy Cao-Thi-My
Hien Nguyen-Thi-Dieu
Duong Vo-Thai
Vu Nguyen-Thien
Sy Duong-Quy
Publication date
06-03-2024
Publisher
Springer Healthcare
Published in
Pulmonary Therapy
Print ISSN: 2364-1754
Electronic ISSN: 2364-1746
DOI
https://doi.org/10.1007/s41030-024-00254-2
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.